

Proposed Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

28. (currently amended) A monoclonal antibody which specifically binds to a 40-O-(2-hydroxyethyl)-rapamycin with a cross-reactivity with rapamycin of less than 30%. specifically recognizes a rapamycin, wherein the rapamycin is (i) rapamycin or (ii) a 40-O-alkylated rapamycin.
29. (canceled)
30. (canceled)
31. (currently amended) A monoclonal antibody of claim 28, obtained by:
 - a) reaction of a 40-O-(2-hydroxyethyl) rapamycin having an activated coupling group at the 28-O position with an immunogenic protein to produce an immunogenic conjugate;
 - b) administration of said immunogenic conjugate to an appropriate animal species to effect immunogenic challenge and recovery of antibody-producing cells sensitized to said conjugate;
 - c) immortalization of said antibody-producing cells; and
 - d) recovery of monoclonal antibody from a selected immortalized cell line thus established.
32. (canceled)
33. (canceled)
34. (canceled)
35. (canceled)
36. (canceled)
37. (canceled)

38. (previously presented) A hybridoma cell line which produces a monoclonal antibody of claim 28.

39. (previously presented) An immunoassay kit for measuring the blood level of a rapamycin, comprising a monoclonal antibody of claim 28.

40. (new) A monoclonal antibody of claim 28 which has a cross-reactivity with rapamycin of less than 10%.